Amgen: Biotech Giant's Path to Growth and Recovery
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Fundamental analysis is key to maximizing stock returns. By evaluating financial health, you can make informed investment choices that lead to higher profits.
22,179 articlesAmgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
AI-driven demand pushed Intel, AMD, Arm and other AI stocks higher today. Learn what drove the rally, what it means f...
As rates likely rise this year, stocks face a new environment. This guide breaks down what that means for the S&P 500...
Rambus rides AI infrastructure tailwinds but keeps a neutral stance as investors weigh valuation against accelerating...
Broadcom is tightening its AI-driven growth narrative with a year-end price target and brisk AI silicon momentum, set...
When a former chief officer sells stock, investors should look beyond the headline. This guide explains why insider m...
Canaccord Genuity lowers AeroVironment's target to $330 but preserves a Buy rating, underscoring long-term optimism a...
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
The Baupost founder made a bold, selective move: trim a large Alphabet stake and pivot to a fintech name that slumped...
Figma trades higher ahead of tonight’s Q1 print, as analysts eye revenue growth and AI momentum. Live coverage tracks...
Snowflake is set to report Q1 FY2027 after the market closes, testing whether AI-driven demand translates into real p...
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...